UK post code lottery slammed by ABPI

27 April 2008

The director general of the Association of the British Pharmaceutical Industry, Richard Barker, has given a detailed criticism of access to medicines under the UK's public health care system. Writing in the Daily Mail newspaper, Dr Barker said that, although "we accept inequality in many areas of life...when it comes to the National Health Service, inequality spells unfairness at times of greatest need."

The injustice is all the greater from the fact that people are paying the same levels of taxes to fund the NHS, but are receiving widely different service from one district to another, he argued. Even worse, there is a growing sense of division between England and the rest of the UK, where some drugs are easier to access and prescription charges are lower or non-existent (Marketletters passim).

Despite official pronouncements from government-appointed figures such as Roger Boyle, the "Heart Czar," the use of statins as a way of lowering cholesterol is "patchy," Dr Barker noted. "It can be three times as high in one Primary Care Trust than the one next door." On cancer treatment, the ABPI director general described the "sub-standard" NHS provision as "a national scandal" in many parts of the country.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight